Orphanet J Rare Dis 2014;9:117
Patients must be at least 18 years old and meet one of the following clinical requirements when GLP-1 therapy begins: A body mass index, or BMI, of 35 or higher A BMI between 30 and 34.99 with at least one qualifying health condition A BMI between 27 and 29.99 with at least one qualifying higher-risk health condition For someone with a BMI between 30 and 34.99, qualifying conditions may include heart failure with preserved ejection fraction, uncontrolled high blood pressure, stage 3a or higher chronic kidney disease, prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease
M., Ferrero, R
L-Carnitine heeft dus meerdere gunstige effecten, waarvan het bekendste de ondersteuning voor vetverlies is
XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease
Its possible that they can cause side effects, such as indigestion, headaches and insomnia
.png)
